Comparison of age-related macular degeneration treatments trials: Lucentis-avastin trial (CATT).
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms CATT
- 07 Jun 2017 Status changed from active, no longer recruiting to completed.
- 29 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Feb 2017.
- 02 May 2016 Long-term results of this trial were published in Ophthalmology, according to an American Academy of Ophthalmology media release.